Deborah Y Park1, Martin C Tom2, Wei Wei3, Surabhi Tewari1, Manmeet S Ahluwalia2, Jennifer S Yu1,4, Samuel T Chao1,4,5, John H Suh1,4,5, David Peereboom1,5, Glen H J Stevens1,5, Gene H Barnett1,5,6, Lilyana Angelov1,5,6, Alireza M Mohammadi1,5,6, Thomas Hogan7, Courtney Kissel7, Brittany Lapin3, Isabel Schuermeyer8, Michael W Parsons9, Richard Naugle1,7, Erin S Murphy10,11,12. 1. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA. 2. Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA. 3. Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue / CA-60, Cleveland, OH, 44195, USA. 4. Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue / CA-50, Cleveland, OH, 44195, USA. 5. Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center and Neurological institute, Cleveland Clinic, Cleveland, OH, USA. 6. Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA. 7. Department of Neuropsychology, Cleveland Clinic, Cleveland, OH, USA. 8. Department of Psychiatry, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA. 9. Neuro-Oncology Center and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. 10. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA. murphye3@ccf.org. 11. Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue / CA-50, Cleveland, OH, 44195, USA. murphye3@ccf.org. 12. Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center and Neurological institute, Cleveland Clinic, Cleveland, OH, USA. murphye3@ccf.org.
Abstract
PURPOSE: Low-grade glioma (LGG) exhibits longer median survival than high-grade brain tumors, and thus impact of our therapies on patient quality of life remains a crucial consideration. This study evaluated the effects of concurrent temozolomide-based chemoradiation (RT + TMZ) or observation on quality of life (QOL) in patients with low-grade glioma. METHODS: We completed a retrospective cross-sectional study of adults with LGG who underwent surgery with known molecular classification from 1980 to 2018. Postoperatively, patients were either observed or received adjuvant concurrent temozolomide-based chemoradiation. EQ-5D and PHQ-9 depression screen were completed before outpatient visits every 2-3 months. Baseline score was defined as ± 30 days within initial operation. RESULTS: Of the 63 patients (mean age 44 ± 17 years, 51% female) with baseline EQ-5D or PHQ-9 depression screen data and at least one follow-up measure, 30 (48%) were observed and 33 (52%) received RT + TMZ. No significant decline was seen in EQ-5D or PHQ-9 scores at 3, 6, 9, 12, and 24 months compared to baseline scores for all patients. At each time point, there was no significant difference between those who were observed or received adjuvant therapy. The linear mixed model estimating PHQ-9 value or EQ-5D index demonstrated that there was no significant difference in PHQ-9 or EQ-5D index between treatment groups (p = 0.42 and p = 0.54, respectively) or time points (p = 0.24 and p = 0.99, respectively). CONCLUSION: Our study found no significant decline in patient QOL or depression scores as assessed by patient- reported outcome measures for patients with low-grade glioma up to 2 years following surgery. We found no difference between RT + TMZ compared to observation during this time frame. Additional follow-up can help identify the longer-term impact of treatment strategy on patient experience.
PURPOSE: Low-grade glioma (LGG) exhibits longer median survival than high-grade brain tumors, and thus impact of our therapies on patient quality of life remains a crucial consideration. This study evaluated the effects of concurrent temozolomide-based chemoradiation (RT + TMZ) or observation on quality of life (QOL) in patients with low-grade glioma. METHODS: We completed a retrospective cross-sectional study of adults with LGG who underwent surgery with known molecular classification from 1980 to 2018. Postoperatively, patients were either observed or received adjuvant concurrent temozolomide-based chemoradiation. EQ-5D and PHQ-9 depression screen were completed before outpatient visits every 2-3 months. Baseline score was defined as ± 30 days within initial operation. RESULTS: Of the 63 patients (mean age 44 ± 17 years, 51% female) with baseline EQ-5D or PHQ-9 depression screen data and at least one follow-up measure, 30 (48%) were observed and 33 (52%) received RT + TMZ. No significant decline was seen in EQ-5D or PHQ-9 scores at 3, 6, 9, 12, and 24 months compared to baseline scores for all patients. At each time point, there was no significant difference between those who were observed or received adjuvant therapy. The linear mixed model estimating PHQ-9 value or EQ-5D index demonstrated that there was no significant difference in PHQ-9 or EQ-5D index between treatment groups (p = 0.42 and p = 0.54, respectively) or time points (p = 0.24 and p = 0.99, respectively). CONCLUSION: Our study found no significant decline in patient QOL or depression scores as assessed by patient- reported outcome measures for patients with low-grade glioma up to 2 years following surgery. We found no difference between RT + TMZ compared to observation during this time frame. Additional follow-up can help identify the longer-term impact of treatment strategy on patient experience.
Authors: Nadia N Laack; Paul D Brown; Robert J Ivnik; Alfred F Furth; Karla V Ballman; Julie E Hammack; Robert M Arusell; Edward G Shaw; Jan C Buckner Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-20 Impact factor: 7.038
Authors: Francesco Pignatti; Martin van den Bent; Desmond Curran; Channa Debruyne; Richard Sylvester; Patrick Therasse; Denes Afra; Philippe Cornu; Michel Bolla; Charles Vecht; Abul B M F Karim Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Jaap C Reijneveld; Martin J B Taphoorn; Corneel Coens; Jacoline E C Bromberg; Warren P Mason; Khê Hoang-Xuan; Gail Ryan; Mohamed Ben Hassel; Roelien H Enting; Alba A Brandes; Antje Wick; Olivier Chinot; Michele Reni; Guy Kantor; Brian Thiessen; Martin Klein; Eugenie Verger; Christian Borchers; Peter Hau; Michael Back; Anja Smits; Vassilis Golfinopoulos; Thierry Gorlia; Andrew Bottomley; Roger Stupp; Brigitta G Baumert Journal: Lancet Oncol Date: 2016-09-27 Impact factor: 41.316
Authors: Erin S Murphy; Charles M Leyrer; Michael Parsons; John H Suh; Samuel T Chao; Jennifer S Yu; Rupesh Kotecha; Xuefei Jia; David M Peereboom; Richard A Prayson; Glen H J Stevens; Gene H Barnett; Michael A Vogelbaum; Manmeet S Ahluwalia Journal: Int J Radiat Oncol Biol Phys Date: 2017-12-21 Impact factor: 7.038
Authors: Martin Klein; Nadine H J Engelberts; Henk M van der Ploeg; Dorotheé G A Kasteleijn-Nolst Trenité; Neil K Aaronson; Martin J B Taphoorn; Hans Baaijen; W Peter Vandertop; Martin Muller; Tjeerd J Postma; Jan J Heimans Journal: Ann Neurol Date: 2003-10 Impact factor: 10.422
Authors: Martin J van den Bent; C Mircea S Tesileanu; Wolfgang Wick; Marc Sanson; Alba Ariela Brandes; Paul M Clement; Sarah Erridge; Michael A Vogelbaum; Anna K Nowak; Jean Français Baurain; Warren P Mason; Helen Wheeler; Olivier L Chinot; Sanjeev Gill; Matthew Griffin; Leland Rogers; Walter Taal; Roberta Rudà; Michael Weller; Catherine McBain; Jaap Reijneveld; Roelien H Enting; Francesca Caparrotti; Thierry Lesimple; Susan Clenton; Anja Gijtenbeek; Elizabeth Lim; Ulrich Herrlinger; Peter Hau; Frederic Dhermain; Iris de Heer; Kenneth Aldape; Robert B Jenkins; Hendrikus Jan Dubbink; Johan M Kros; Pieter Wesseling; Sarah Nuyens; Vassilis Golfinopoulos; Thierry Gorlia; Pim French; Brigitta G Baumert Journal: Lancet Oncol Date: 2021-05-14 Impact factor: 54.433
Authors: Kurt A Jaeckle; Karla V Ballman; Martin van den Bent; Caterina Giannini; Evanthia Galanis; Paul D Brown; Robert B Jenkins; J Gregory Cairncross; Wolfgang Wick; Michael Weller; Kenneth D Aldape; Jesse G Dixon; S Keith Anderson; Jane H Cerhan; Jeffrey S Wefel; Martin Klein; Stuart A Grossman; David Schiff; Jeffrey J Raizer; Frederick Dhermain; Donald G Nordstrom; Patrick J Flynn; Michael A Vogelbaum Journal: Neuro Oncol Date: 2021-03-25 Impact factor: 12.300